COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases
José M. Serra López-Matencio, Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, Santos Castañeda · 2023
Read COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases by José M. Serra López-Matencio, Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, Santos Castañeda (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10747214.txt.
Description
In a 2023 review, José M. Serra López-Matencio and co-authors examine COVID-19 vaccination for patients whose immune systems are medically suppressed. People with immune-mediated inflammatory diseases take drugs that blunt immunity, and vaccine responses were a pressing unknown. Evidence from flu and other vaccines suggested these drugs weaken antibody responses.
The review gathers what studies found for COVID vaccines drug by drug. Pausing one common drug, methotrexate, for two weeks after vaccination appeared to improve response. Other agents pointed the same way, but firm rules are lacking. The authors weigh the flare risk of pausing treatment against the benefit of stronger protection, and map where guidance can and cannot yet be given.
Catalog record
| CREATOR | José M. Serra López-Matencio, Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, Santos Castañeda |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |